Bristol-Myers plans to divest Celgene’s psoriasis drugAcquisitions, Analysts, Autoimmune Diseases, Autoimmune Disorders, Blockbusters, Business, Cancer, European Commission, Immunology, M&A, Plaque Psoriasis, Psoriasis, Shares, Stocks, Tyrosine Kinase 2 Inhibitors, U.S. Federal Trade Commission (FTC)Bristol-Myers Squibb Co. offered to divest Celgene Corp.’s psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal. Read more June 24, 2019/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2019-06-24 07:47:142019-06-24 14:08:20Bristol-Myers plans to divest Celgene’s psoriasis drug
